Trials / Completed
CompletedNCT06482112
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
A Phase 2a Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Different Dosing Regimens of Efinopegdutide (MK-6024) in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.
Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Non-alcoholic Fatty Liver Disease
- Nonalcoholic Fatty Liver Disease
- Liver Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Efinopegdutide | SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm |
Timeline
- Start date
- 2024-07-29
- Primary completion
- 2025-06-27
- Completion
- 2025-06-27
- First posted
- 2024-07-01
- Last updated
- 2025-07-15
Locations
39 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06482112. Inclusion in this directory is not an endorsement.